Olr1235 inhibitors are a specialized class of chemical compounds that are specifically designed to interact with and inhibit the function of the Olr1235 receptor, a member of the olfactory receptor family within the G protein-coupled receptor (GPCR) superfamily. Olr1235 receptors play a critical role in the olfactory system, which is responsible for the detection and interpretation of odorant molecules, ultimately contributing to the sense of smell. These inhibitors function by binding to the receptor's active site or other regulatory regions, thereby blocking the receptor's ability to interact with its natural ligands. This interaction prevents the receptor from undergoing the conformational changes necessary for the activation of intracellular signaling pathways that typically follow ligand binding. The design of Olr1235 inhibitors often involves detailed structural studies of the receptor, utilizing techniques such as X-ray crystallography, molecular dynamics simulations, and cryo-electron microscopy. These studies provide crucial insights into the receptor's binding pockets and other important features, allowing for the creation of inhibitors that are highly specific to the Olr1235 receptor.
Chemically, Olr1235 inhibitors exhibit a diverse range of structures and properties, reflecting the various approaches used in their synthesis and development. These compounds may be small, hydrophobic molecules capable of easily crossing cellular membranes to reach their target receptors, or they may be larger, more complex molecules that require sophisticated synthetic techniques to achieve the desired binding affinity and selectivity. The synthetic pathways used to create Olr1235 inhibitors often involve multiple steps of organic synthesis, including the formation of key functional groups that are critical for binding to the receptor. After synthesis, these compounds undergo rigorous characterization using analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC) to confirm their structural integrity, purity, and inhibitory activity. The study of Olr1235 inhibitors not only advances our understanding of the specific mechanisms by which this olfactory receptor operates but also contributes to a broader knowledge of GPCR modulation. This research provides valuable insights into how these complex receptors can be selectively targeted and regulated by small molecules, which is essential for deepening our understanding of the molecular processes involved in sensory perception, particularly in the context of olfaction.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR inhibitor, potentially interrupts cell signaling and proliferation in certain cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Raf kinase inhibitor, potentially disrupts cell signaling in various malignancies. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Multi-kinase inhibitor, might affect VEGFR, FGFR, PDGFR, RET, and KIT pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, potentially modulates cell signaling in melanoma and other cancers. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Targets EGFR, HER2, and HER4, potentially interrupting proliferative signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, could hinder cell growth in breast cancer. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, may affect non-small cell lung cancer with specific mutations. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, potentially blocks signaling in lung cancer. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, might affect melanoma cells with BRAF mutations. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
CDK4/6 inhibitor, potentially delays cell cycle progression in hormone receptor-positive breast cancer. | ||||||